Nov 7 (Reuters) - Agenus Inc said a mid-stage trialof its experimental genital herpes vaccine reduced the rate atwhich patients' were shedding the virus.
The 15 percent reduction in viral shedding in patientsreceiving the vaccine compared to those on a placebo, who showedno reduction.
The mid-stage trial had 80 patients with a history of 1-9herpes recurrences within the prior 12 months. Of them, 70received the vaccine, HerpV, and 10 received placebo.
- Pharmaceuticals & Drug Trials